NCT00478075View on ClinicalTrials.gov

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

November 30, 2007

Study Completion Date

June 30, 2009

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
DRUG

bortezomib

OTHER

immunologic technique

RADIATION

samarium Sm 153 lexidronam pentasodium

Trial Locations (3)

32224

Mayo Clinic - Jacksonville, Jacksonville

55905

Mayo Clinic Cancer Center, Rochester

85259-5499

Mayo Clinic Scottsdale, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER